
Kate Blakeman will focus on the people who shape the profession.
The British Equine Veterinary Association (BEVA) has named University of Nottingham Professor Kate Blakeman as president for 2026/27.
Kate, who will succeed Imogen Burrows at the end of BEVA Congress, plans to use her presidential year to champion the individuals who shape the equine veterinary field.
She said: “During my presidential year, I want to focus on the people who make equine practice what it is. We don't always see the pressures faced by colleagues working in different roles, practices or sectors, but we're all part of one profession and we have far more in common than not.
"My goal is to create more opportunities for people from different parts of the profession to learn from one another, understand each other's challenges and work together on shared solutions.”
A graduate of the University of Liverpool, Kate spent 16 years in ambulatory equine practice, developing a particular interest in stud medicine. She has worked in practices across the UK and Australia, joining the University of Nottingham in 2023 as assistant clinical professor in equine practice.
Kate’s experience in academia and equine practice her a perspective that spans clinical practice, veterinary education and professional development. Her work on BEVA council saw her lead work to update pregnancy guidance for equine practitioners, develop BEVA’s career support programmes and chair BEVA’s Clinical Practice Committee.
Kate added: "Having benefited enormously from the support, friendship and opportunities BEVA has provided throughout my career, it is a privilege to serve as President and help shape the future of the profession. Horses will always be our focus. But it’s the people who make the profession what it is.”
Kate will be joined by James Crabtree, who becomes BEVA president elect, and Nicky Housby-Skeggs as junior vice president.
Image (C) Louis James-Parker.



Companies marketing medicines for small pets exempt from authorisation must submit their annual return to the Veterinary Medicines Directorate (VMD) by 30 November 2026.